

Corporate fact sheet

About APR Applied Pharma Research s.a.

APR is a **Swiss, independent developer of science driven, patent protected Healthcare products.**

APR identifies, develops and commercializes value added products (Rx, OTC, Medical Device and Nutritional products) which can provide meaningful benefits through improved efficacy, safety or patient convenience, by applying advanced pharmaceutical patented technologies and pharma development expertise in niche and rare diseases on a global basis.

In particular, APR is currently focused on 2 areas:

- internally developed and financed (alone or together with our co-development partners) proprietary, value added **products to be licensed** to healthcare companies for their commercialization
- support to third party projects by offering **added value R&D services** (for promotion, marketing and distribution) under contract and fee for service arrangements.

APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of innovative products at different stages of development. The products developed or under development at APR range from Rx to OTC pharmaceutical products and include medical devices as well as nutritional supplements for targeted disease areas.

Examples of marketed products include Cambia (www.cambiarx.com), Zuplenz (www.zuplenz.com), Nexodyn® AcidOxidizing Solution (AOS) and PKU GOLIKE®.

The company's R&D efforts are currently focused on the development of improved treatments for rare inherited metabolic disorders (aminoacido-pathies), ocular diseases and rare dermatological diseases.

APR provides a wide range of services for the pharmaceutical and pharmacological industry on a contract basis: Research and Development services with complete supervision, management and execution of the entire project, development of oral and topical formulation and drug delivery technologies (pharma, nutraceuticals, dermocosmetics, Medical Devices).

APR Applied Pharma Research SA has entered into licensing and healthcare partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis. The company has started up a direct sale and marketing organizations in selected countries in rare disease products area.